MAGEA3 and melanoma: TCR-T based strategies have been preliminarily exploited in both solid and hematologic malignancies.7 In this regard, malignant melanoma has been a role model because of its highly immunogenic nature.8 Moreover, prior identified TCR targetable TAAs include melanoma differentiation antigens, such as MART1, cancer/testis antigens including NYESO and the MAGE-family proteins, as well as viral antigens.1 Up to 80%-95% of melanomas express MART1.9 Similarly, NYESO and MAGE-A3 have been described to be present in approximately 52%10 and 62%11of melanomas.